Thurston, Springer, Miller, Herd & Titak, Inc. Bristol Myers Squibb CO Transaction History
Thurston, Springer, Miller, Herd & Titak, Inc.
- $46.2 Million
- Q3 2025
A detailed history of Thurston, Springer, Miller, Herd & Titak, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Thurston, Springer, Miller, Herd & Titak, Inc. holds 40 shares of BMY stock, worth $1,866. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40
Previous 9,104
99.56%
Holding current value
$1,866
Previous $421,000
99.76%
% of portfolio
0.0%
Previous 0.06%
Shares
6 transactions
Others Institutions Holding BMY
# of Institutions
2,668Shares Held
1.56BCall Options Held
24.3MPut Options Held
25.7M-
Vanguard Group Inc Valley Forge, PA196MShares$9.14 Billion0.14% of portfolio
-
Black Rock Inc. New York, NY159MShares$7.4 Billion0.15% of portfolio
-
State Street Corp Boston, MA96.6MShares$4.51 Billion0.16% of portfolio
-
Jpmorgan Chase & CO New York, NY86.2MShares$4.02 Billion0.26% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA73MShares$3.41 Billion0.55% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $99.2B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...